ArticleEpigenetics & chromatin2025
SRP/dGATAb modulates the ecdysone response bidirectionally via locus-specific regulatory landscape.
Article in Epigenetics & chromatin, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundSteroid hormones drive the transcription of developmental genes by activating distinct sets of enhancers across tissues and developmental contexts, but the mechanisms that target specific enhancers remain incompletely understood, even in model organisms. It has been proposed that selective binding of nuclear receptors occurs at regulatory sites primed by other classes of DNA-binding transcription factors. However, direct studies of cooperation between nuclear receptors and different transcription factors remain limited. A previous study suggested that the GATA family factor SRP/dGATAb primes regulatory sites in S2 Schneider cells for activation by 20-hydroxyecdysone (20E), the principal steroid hormone in Drosophila development. Yet the genome-wide impact of SRP/dGATAb depletion on transcriptional responses to 20E has not been examined.
resultsWe investigated the role of SRP/dGATAb in the response of S2 Schneider cells to 20E using SRP/dGATAb depletion via RNA interference. Combined RNA-Seq and ChIP-Seq analyses identified primary targets of SRP/dGATAb that (i) are transcriptionally induced by 20E and (ii) contain binding sites for both EcR and SRP/dGATAb. SRP/dGATAb depletion altered the transcription of different 20E-induced genes in opposite ways. For one subset of 20E-activated genes whose expression decreased upon depletion, SRP/dGATAb regulated active regulatory sites marked by H3K27Ac and enriched with SRP/dGATAb motifs. In these loci, SRP/dGATAb depletion reduced EcR binding at co-bound sites, demonstrating a priming role for this GATA family protein. In contrast, for a second subset of 20E-activated but SRP/dGATAb-suppressed genes (i.e., genes whose expression increased upon SRP/dGATAb depletion), SRP/dGATAb and EcR co-bound sites exhibited undisturbed EcR binding. Notably, the overall level of H3K27 acetylation at these loci increased upon SRP/dGATAb depletion.
conclusionsOur data indicate that SRP/dGATAb positively regulates 20E-inducible transcription in S2 Schneider cells for some genes, functioning as a priming factor that facilitates EcR recruitment and chromatin acetylation. In contrast, for another subset of 20E-inducible genes, SRP/dGATAb exerts a negative regulatory effect, restraining activity of the regulatory sites.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.